Duvelisib Plus Docetaxel In Recurrent/Metastatic HNSCC
Status:
Not yet recruiting
Trial end date:
2023-09-01
Target enrollment:
Participant gender:
Summary
This trial that is investigating a medication called duvelisib in combination with docetaxel
for the treatment of squamous cell carcinoma of the head and neck (SCCHN) that has returned
or spread outside the head and neck area.
The names of the study drugs involved in this study are:
- Duvelisib (PI3K inhibitor)
- Docetaxel chemotherapy